Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 310, Issue 7, 2016, Pages L593-L602

  Salomon, Johanna J ^a   Spahn, Stephan ^a   Wang, Xiaohui ^b   Füllekrug, Joachim ^a   Bertrand, Carol A ^b   Mall, Marcus A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell model; Cl channels; Cystic fibrosis; Epithelial ion transport; SLC26A9

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; 5 NITRO 2 (3 PHENYLPROPYLAMINO)BENZOIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALNEXIN; CARRIER PROTEINS AND BINDING PROTEINS; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GIANTIN; ISOBUTYLMETHYLXANTHINE; MATRIX PROTEIN; MESSENGER RNA; NIFLUMIC ACID; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; SOLUTE CARRIER FAMILY 26 MEMBER A9; UNCLASSIFIED DRUG; BICARBONATE CHLORIDE ANTIPORTER; SLC26A9 PROTEIN, RAT;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BIOTINYLATION; CELL SURFACE; CELLULAR DISTRIBUTION; CHLORIDE CURRENT; CONTROLLED STUDY; CYSTIC FIBROSIS; DEGLYCOSYLATION; ENDOPLASMIC RETICULUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; INTRACELLULAR SPACE; LUNG FIBROSIS; NONHUMAN; OSMOREGULATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; RETROVIRIDAE; RNA INTERFERENCE; SHORT CIRCUIT CURRENT; STABLE EXPRESSION; THYROID FOLLICULAR CELL; WESTERN BLOTTING; WHOLE CELL PATCH CLAMP; ANIMAL; BIOSYNTHESIS; CELL CULTURE; EPITHELIUM CELL; FISCHER 344 RAT; GENE EXPRESSION; GENETICS; MEMBRANE POTENTIAL; MOLECULAR CLONING;

ANIMALS; CELLS, CULTURED; CHLORIDE-BICARBONATE ANTIPORTERS; CLONING, MOLECULAR; CYSTIC FIBROSIS; EPITHELIAL CELLS; GENE EXPRESSION; MEMBRANE POTENTIALS; OSMOREGULATION; RATS, INBRED F344;

EID: 84984662478     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00321.2015     Document Type: Article

References (43)

1. Anagnostopoulou P, Dai L, Schatterny J, Hirtz S, Duerr J, Mall MA. Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice. Eur Respir J 36: 1436-1447, 2010.
2. Anagnostopoulou P, Riederer B, Duerr J, Michel S, Binia A, Agrawal R, Liu X, Kalitzki K, Xiao F, Chen M, Schatterny J, Hartmann D, Thum T, Kabesch M, Soleimani M, Seidler U, Mall MA. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 122: 3629-3634, 2012.
3. Avella M, Loriol C, Boulukos K, Borgese F, Ehrenfeld J. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J Cell Physiol 226: 212-223, 2011.
4. Bakouh N, Bienvenu T, Thomas A, Ehrenfeld J, Liote H, Roussel D, Duquesnoy P, Farman N, Viel M, Cherif-Zahar B, Amselem S, Taam RA, Edelman A, Planelles G, Sermet-Gaudelus I. Characterization of SLC26A9 in patients with CF-like lung disease. Hum Mutat 34: 1404-1414, 2013.
5. Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol 133: 421-438, 2009.
6. + transporter. J Membr Biol 228: 125-140, 2009.
7. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O’Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834, 1990.
8. - channel regulated by the WNK kinases. J Physiol 584: 333-345, 2007.
9. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for highthroughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-C1742, 2001.
10. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 82: 245-289, 2002.
11. Li J, Xia F, Reithmeier RA. N-glycosylation and topology of the human SLC26 family of anion transport membrane proteins. Am J Physiol Cell Physiol 306: C943-C960, 2014.
12. Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 133: 151-161, 2014.
13. 3- transport and reduces survival in CFTRdeficient mice. Pflügers Arch 467: 1261-1275, 2015.
14. Lohi H, Kujala M, Makela S, Lehtonen E, Kestila M, Saarialho-Kere U, Markovich D, Kere J. Functional characterization of three novel tissue-specific anion exchangers SLC26A7,-A8, and-A9. J Biol Chem 277: 14246-14254, 2002.
15. - transport by bicarbonate. Cell Physiol Biochem 22: 15-30, 2008.
16. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, Verkman AS. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 277: 37235-37241, 2002.
17. - secretion in human airway epithelia. Am J Respir Cell Mol Biol 23: 283-289, 2000.
18. Mall M, Gonska T, Thomas J, Hirtz S, Schreiber R, Kunzelmann K. Activation of ion secretion via proteinase-activated receptor-2 in human colon. Am J Physiol Gastrointest Liver Physiol 282: G200-G210, 2002.
19. Mall MA, Galietta LJ. Targeting ion channels in cystic fibrosis. J Cyst Fibros 14: 561-570, 2015.
20. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J 44: 1042-1054, 2014.
21. Miller MR, Soave D, Li W, Gong J, Pace RG, Boëlle PY, Cutting GR, Drumm ML, Knowles MR, Sun L, Rommens JM, Accurso F, Durie PR, Corvol H, Levy H, Sontag MK, Strug LJ. Variants in solute carrier SLC26A9 modify prenatal exocrine pancreatic damage in cystic fibrosis. J Pediatr 166: 1152-1157, 2015.
22. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124: 125-137, 2004.
23. Namkung W, Park J, Seo Y, Verkman AS. Novel amino-carbonitrilepyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist. Mol Pharmacol 84: 384-392, 2013.
24. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571, 2005.
25. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663-1672, 2011.
26. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, McCann JD, Klinger KW, Smith AE, Welsh MJ. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347: 358-363, 1990.
27. Richardson C, Sakamoto K, de los Heros P, Deak M, Campbell DG, Prescott AR, Alessi DR. Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and-independent pathways. J Cell Sci 124: 789-800, 2011.
28. Schreiber R, Uliyakina I, Kongsuphol P, Warth R, Mirza M, Martins JM, Kunzelmann K. Expression and function of epithelial anoctamins. J Biol Chem 285: 7838-7845, 2010.
29. Schuck S, Manninen A, Honsho M, Füllekrug J, Simons K. Generation of single and double knockdowns in polarized epithelial cells by retrovirus-mediated RNA interference. Proc Natl Acad Sci USA 101: 4912-4917, 2004.
30. - channel by niflumic acid. Mol Membr Biol 21: 27-38, 2004.
31. Sheppard DN. CFTR channel pharmacology: novel pore blockers identified by high-throughput screening. J Gen Physiol 124: 109-113, 2004.
32. Sheppard DN, Carson MR, Ostedgaard LS, Denning GM, Welsh MJ. Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am J Physiol Lung Cell Mol Physiol 266: L405-L413, 1994.
33. + channel to the cell surface. J Clin Invest 105: 45-53, 2000.
34. Soave D, Miller MR, Keenan K, Li W, Gong J, Ip W, Accurso F, Sun L, Rommens JM, Sontag M, Durie PR, Strug LJ. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosisrelated diabetes: a Mendelian randomization study. Diabetes 63: 2114-2119, 2014.
35. Stutts MJ, Fitz JG, Paradiso AM, Boucher RC. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am J Physiol Cell Physiol 267: C1442-C1451, 1994.
36. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson PF, Parekh RV, Zelenika D, Blackman SM, Corey M, Doshi VK, Henderson L, Naughton KM, O’Neal WK, Pace RG, Stonebraker JR, Wood SD, Wright FA, Zielenski J, Clement A, Drumm ML, Boëlle PY, Cutting GR, Knowles MR, Durie PR, Strug LJ. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44: 562-569, 2012.
37. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825-18830, 2009.
38. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108: 18843-18888, 2011.
39. Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13: 29-36, 2014.
40. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373: 220-231, 2015.
41. Xu J, Song P, Miller ML, Borgese F, Barone S, Riederer B, Wang Z, Alper SL, Forte JG, Shull GE, Ehrenfeld J, Seidler U, Soleimani M. Deletion of the chloride transporter Slc26a9 causes loss of tubulovesicles in parietal cells and impairs acid secretion in the stomach. Proc Natl Acad Sci USA 105: 17955-17960, 2008.
42. Yang CL, Liu X, Paliege A, Zhu X, Bachmann S, Dawson DC, Ellison DH. WNK1 and WNK4 modulate CFTR activity. Biochem Biophys Res Commun 353: 535-540, 2007.
43. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11: 237-245, 2012.